BPX-01

Despite having hit its primary endpoint in the Phase 2b clinical trial of acne-treating BPX-01, Biopharmx Corp (NYSE: BPMX) plunged last week on a secondary endpoint miss on the Investigator’s Global Assessment (IGA) scale for acne severity. BioPharmX now looks to hit IGA goals as a coprimary...

Biopharmx Corp (NYSE: BPMX) shares have moved 38 percent higher in 2017 as the company progresses its dermatology-centric drugs through the pipeline. The Silicon Valley-based pharmaceutical currently has its lead candidate, BPX-01, undergoing both a Phase 2b dose finding trial for the treatment of...